Interface Biologics

Interface Biologics is a Canadian company based in Toronto, specializing in biomedical polymer and surface-modification technologies.

The company focuses on enhancing the safety and effectiveness of medical devices that interact with blood, tissue, or other biological fluids. Their core technologies include surface-modifying macromolecules and polymer-enabled combination drug delivery devices. The Endexo® technology is part of their surface-modification platform, which improves biocompatibility and helps reduce complications such as infections and thrombus formation on medical devices. Additionally, Interface Biologics has developed sustained local drug delivery technology, particularly aimed at ophthalmology applications. The company's innovations have been utilized in FDA-approved medical devices and have undergone clinical validation for their effectiveness in reducing infection and thrombus-related issues. Interface Biologics originated as a spinoff from the University of Toronto and has made significant strides in the biomedical field.